NurOwn stem cell therapy for early ALS
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This study tests a new stem cell treatment called NurOwn for people with early ALS (within 2 years of symptoms) who still have good breathing and daily function. The goal is to see if it can slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- Your ALS diagnosis is 'lab-supported probable,' 'probable,' or 'definite'
- Your ALS symptoms (like muscle weakness) started less than 2 years ago
- You have a score of 45 or less on the ALS functional rating scale (ALSFRS-R)
- Your breathing test (upright SVC) is at least 65% of normal for your age, height, and gender
- You have not had any stem cell therapy before
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether injecting neural stem cells into the spine can slow down ALS. It is for people with rapidly progressing ALS who have good lung function and a caregiver to help with visits.
This trial tests a new treatment made from stem cells (called XS228CN) injected into the spine. It is primarily a safety study, but doctors will also watch for any signs the treatment may slow ALS progression.
This study tests whether bone-marrow stem cells can improve nerve function in people with nerve damage that usually doesn’t recover with current care. It also checks whether the treatment is safe and whether people can be followed over time with repeated nerve exams.
This trial tests a new type of cell therapy called regulatory T cells (Tregs) for people with neurodegenerative diseases like ALS. The goal is to see if these cells can slow down the disease.
This trial tests a nasal drop made from tiny cell particles (extracellular vesicles) for ALS. The goal is to see if it's safe and if it can slow down the disease. It may be an option if your ALS is in the early to moderate stage.
This trial is testing a new way to deliver nerve growth factor using tiny, protective nanocapsules injected into the body. The goal is to see if this treatment can slow the progression of ALS (Lou Gehrig's disease) and help maintain muscle strength and breathing function.
Hear when a new Amyotrophic Lateral Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.